Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
Cipla’s launch of Afrezza, India’s first inhalable insulin, marks a transformative milestone in diabetes care within the country. Developed by MannKind Corporation, Afrezza provides a needle-free, rapid-acting insulin alternative that is inhaled through a compact device, offering convenience and reducing the barriers posed by injectable therapies.
This innovative approach targets adults with type 1 and type 2 diabetes, particularly those struggling with needle aversion or adherence issues. Its rapid onset of action helps better manage post-meal blood sugar spikes, potentially improving overall glycemic control.
Given India’s staggering diabetes prevalence, with millions requiring insulin therapy, this introduction could significantly enhance accessibility to advanced and patient-friendly treatment options, aligning with Cipla’s commitment to transforming healthcare outcomes.
